FI117974B - Parannettu rokote immunisointiin TBE-virusinfektioita vastaan ja menetelmä sen valmistamiseksi - Google Patents
Parannettu rokote immunisointiin TBE-virusinfektioita vastaan ja menetelmä sen valmistamiseksi Download PDFInfo
- Publication number
- FI117974B FI117974B FI953371A FI953371A FI117974B FI 117974 B FI117974 B FI 117974B FI 953371 A FI953371 A FI 953371A FI 953371 A FI953371 A FI 953371A FI 117974 B FI117974 B FI 117974B
- Authority
- FI
- Finland
- Prior art keywords
- protein
- virus
- proteins
- prm
- tbe
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 39
- 230000003053 immunization Effects 0.000 title claims description 38
- 238000002649 immunization Methods 0.000 title claims description 35
- 238000002360 preparation method Methods 0.000 title claims description 30
- 238000000034 method Methods 0.000 title claims description 19
- 230000009385 viral infection Effects 0.000 title claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 56
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 40
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 36
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 33
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 33
- 101710085938 Matrix protein Proteins 0.000 claims abstract description 18
- 101710127721 Membrane protein Proteins 0.000 claims abstract description 18
- 101800001127 Protein prM Proteins 0.000 claims abstract description 14
- 239000013600 plasmid vector Substances 0.000 claims abstract description 10
- 241000700605 Viruses Species 0.000 claims description 90
- 101710204837 Envelope small membrane protein Proteins 0.000 claims description 69
- 101710088839 Replication initiation protein Proteins 0.000 claims description 60
- 208000015181 infectious disease Diseases 0.000 claims description 33
- 239000002245 particle Substances 0.000 claims description 31
- 230000002458 infectious effect Effects 0.000 claims description 25
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 15
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 15
- 238000004113 cell culture Methods 0.000 claims description 11
- 230000014509 gene expression Effects 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 150000002632 lipids Chemical class 0.000 claims description 3
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 241000036848 Porzana carolina Species 0.000 claims 1
- 101710166632 Pre-core protein X Proteins 0.000 claims 1
- 241000710831 Flavivirus Species 0.000 abstract description 11
- 239000013598 vector Substances 0.000 abstract description 11
- 108091026890 Coding region Proteins 0.000 abstract description 10
- 206010054261 Flavivirus infection Diseases 0.000 abstract description 3
- 208000004006 Tick-borne encephalitis Diseases 0.000 description 61
- 210000004027 cell Anatomy 0.000 description 43
- 239000013612 plasmid Substances 0.000 description 38
- 239000000427 antigen Substances 0.000 description 25
- 108091007433 antigens Proteins 0.000 description 25
- 102000036639 antigens Human genes 0.000 description 25
- 241000699670 Mus sp. Species 0.000 description 22
- 239000002773 nucleotide Substances 0.000 description 21
- 108020004414 DNA Proteins 0.000 description 20
- 230000035772 mutation Effects 0.000 description 20
- 125000003729 nucleotide group Chemical group 0.000 description 20
- 238000002965 ELISA Methods 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 17
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 13
- 230000028993 immune response Effects 0.000 description 13
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 229940023146 nucleic acid vaccine Drugs 0.000 description 11
- 230000003612 virological effect Effects 0.000 description 11
- 101710145006 Lysis protein Proteins 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 9
- 108020004705 Codon Proteins 0.000 description 8
- 230000035931 haemagglutination Effects 0.000 description 8
- 230000009257 reactivity Effects 0.000 description 8
- 239000012528 membrane Substances 0.000 description 7
- 230000001681 protective effect Effects 0.000 description 7
- 238000004062 sedimentation Methods 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 101150013191 E gene Proteins 0.000 description 5
- 102000002265 Human Growth Hormone Human genes 0.000 description 5
- 108010000521 Human Growth Hormone Proteins 0.000 description 5
- 239000000854 Human Growth Hormone Substances 0.000 description 5
- 108091061960 Naked DNA Proteins 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 239000013615 primer Substances 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 108010006785 Taq Polymerase Proteins 0.000 description 4
- 108020005038 Terminator Codon Proteins 0.000 description 4
- 241000710771 Tick-borne encephalitis virus Species 0.000 description 4
- 229920004890 Triton X-100 Polymers 0.000 description 4
- 239000013504 Triton X-100 Substances 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 241000272814 Anser sp. Species 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 241000031091 Synodontis clarias Species 0.000 description 3
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000037432 silent mutation Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 241000710842 Japanese encephalitis virus Species 0.000 description 2
- 241000713333 Mouse mammary tumor virus Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 101150064860 PRM gene Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 150000003278 haem Chemical class 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000004779 membrane envelope Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 101150111062 C gene Proteins 0.000 description 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 101800001632 Envelope protein E Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- 241000132179 Eurotium medium Species 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 101150033828 NS1 gene Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- -1 Nucleotide Amino Acid Chemical class 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000006800 cellular catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001738 isopycnic centrifugation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000009962 secretion pathway Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
- C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0135294A AT402897B (de) | 1994-07-08 | 1994-07-08 | Verbesserte vakzine zur immunisierung gegen tbe-virusinfektionen sowie ein verfahren zu dessen herstellung |
| AT135294 | 1994-07-08 | ||
| AT0087195A AT405607B (de) | 1995-05-23 | 1995-05-23 | Verbesserte vakzine zur immunisierung gegen tbe-virusinfektionen sowie ein verfahren zu dessen herstellung |
| AT87195 | 1995-05-23 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI953371A0 FI953371A0 (fi) | 1995-07-07 |
| FI953371A FI953371A (fi) | 1996-01-09 |
| FI117974B true FI117974B (fi) | 2007-05-15 |
Family
ID=25594155
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI953371A FI117974B (fi) | 1994-07-08 | 1995-07-07 | Parannettu rokote immunisointiin TBE-virusinfektioita vastaan ja menetelmä sen valmistamiseksi |
| FI20070041A FI118222B (fi) | 1994-07-08 | 2007-01-17 | Parannettu rokote Flavivirusinfektioiden vastaiseen immunisointiin |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI20070041A FI118222B (fi) | 1994-07-08 | 2007-01-17 | Parannettu rokote Flavivirusinfektioiden vastaiseen immunisointiin |
Country Status (9)
| Country | Link |
|---|---|
| EP (2) | EP0869184B1 (ru) |
| AT (2) | ATE198909T1 (ru) |
| CZ (1) | CZ282927B6 (ru) |
| DE (2) | DE59509667D1 (ru) |
| DK (2) | DK0869184T3 (ru) |
| ES (2) | ES2165109T3 (ru) |
| FI (2) | FI117974B (ru) |
| HU (2) | HU219503B (ru) |
| RU (1) | RU2150294C1 (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69833388D1 (de) * | 1997-11-20 | 2006-04-13 | Us Army Medical Res Materiel C | Dna impfstoffe gegen zecken-flavivieren |
| US7425437B2 (en) | 1999-11-26 | 2008-09-16 | Crucell Holland B.V. | Vaccines against West Nile Virus |
| EP1572941A4 (en) * | 2002-02-26 | 2009-03-18 | Maxygen Inc | NEW FLAVIVIRUS ANTIGENES |
| CA2591665C (en) | 2004-12-20 | 2015-05-05 | Crucell Holland B.V. | Binding molecules capable of neutralizing west nile virus and uses thereof |
| US8052974B2 (en) | 2005-05-12 | 2011-11-08 | Crucell Holland B.V. | Host cell specific binding molecules capable of neutralizing viruses and uses thereof |
| US8211431B2 (en) | 2006-06-06 | 2012-07-03 | Crucell Holland B.V. | Human binding molecules having killing activity against staphylococci and uses thereof |
| WO2010008411A1 (en) | 2007-11-09 | 2010-01-21 | The Salk Institute For Biological Studies | Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2074422T3 (es) * | 1987-03-20 | 1995-09-16 | Immuno Ag | Moleculas de adn y arn del subtipo accidental del virus fsma, polipeptidos, que son codificados por estas moleculas, y su uso. |
| MY109299A (en) * | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
| WO1992003161A1 (en) | 1990-08-27 | 1992-03-05 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Flavivirus envelope proteins with increased immunogenicity for use in immunization against virus infection |
| DK0584348T3 (da) | 1992-03-11 | 2005-09-19 | Powderject Vaccines Inc | Genetisk vaccine mod immundefektvirusser |
-
1995
- 1995-06-21 HU HU9501832A patent/HU219503B/hu not_active IP Right Cessation
- 1995-06-21 HU HU9903233A patent/HU224199B1/hu not_active IP Right Cessation
- 1995-07-06 AT AT95890132T patent/ATE198909T1/de active
- 1995-07-06 DE DE59509667T patent/DE59509667D1/de not_active Expired - Lifetime
- 1995-07-06 ES ES98107383T patent/ES2165109T3/es not_active Expired - Lifetime
- 1995-07-06 ES ES95890132T patent/ES2155510T3/es not_active Expired - Lifetime
- 1995-07-06 AT AT98107383T patent/ATE206459T1/de active
- 1995-07-06 EP EP98107383A patent/EP0869184B1/de not_active Expired - Lifetime
- 1995-07-06 EP EP95890132A patent/EP0691404B1/de not_active Expired - Lifetime
- 1995-07-06 DK DK98107383T patent/DK0869184T3/da active
- 1995-07-06 DK DK95890132T patent/DK0691404T3/da active
- 1995-07-06 DE DE59508988T patent/DE59508988D1/de not_active Expired - Lifetime
- 1995-07-07 FI FI953371A patent/FI117974B/fi not_active IP Right Cessation
- 1995-07-07 RU RU95113194/14A patent/RU2150294C1/ru not_active IP Right Cessation
- 1995-07-07 CZ CZ951769A patent/CZ282927B6/cs not_active IP Right Cessation
-
2007
- 2007-01-17 FI FI20070041A patent/FI118222B/fi not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DK0869184T3 (da) | 2001-12-17 |
| HU9903233D0 (en) | 1999-11-29 |
| FI953371A0 (fi) | 1995-07-07 |
| CZ176995A3 (en) | 1996-01-17 |
| EP0869184A3 (de) | 1999-05-12 |
| HU219503B (hu) | 2001-04-28 |
| DK0691404T3 (da) | 2001-03-19 |
| RU2150294C1 (ru) | 2000-06-10 |
| DE59509667D1 (de) | 2001-11-08 |
| EP0691404B1 (de) | 2001-01-24 |
| EP0869184B1 (de) | 2001-10-04 |
| HU9501832D0 (en) | 1995-08-28 |
| CZ282927B6 (cs) | 1997-11-12 |
| ES2165109T3 (es) | 2002-03-01 |
| ATE198909T1 (de) | 2001-02-15 |
| HU224199B1 (hu) | 2005-06-28 |
| FI20070041A (fi) | 2007-01-17 |
| ES2155510T3 (es) | 2001-05-16 |
| EP0691404A2 (de) | 1996-01-10 |
| FI118222B (fi) | 2007-08-31 |
| FI953371A (fi) | 1996-01-09 |
| ATE206459T1 (de) | 2001-10-15 |
| EP0869184A2 (de) | 1998-10-07 |
| HUT72395A (en) | 1996-04-29 |
| DE59508988D1 (de) | 2001-03-01 |
| EP0691404A3 (de) | 1997-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020200303B9 (en) | Novel multivalent nanoparticle-based vaccines | |
| JP2024050973A (ja) | ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン | |
| Konishi et al. | Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection | |
| EP1078092B1 (en) | Expression vectors for stimulating an immune response and methods of using the same | |
| AU692152B2 (en) | Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide, and their uses in vaccines and disease treatments | |
| CN112469661A (zh) | 具有新结构组分的纳米粒疫苗 | |
| FI118222B (fi) | Parannettu rokote Flavivirusinfektioiden vastaiseen immunisointiin | |
| JP3510249B2 (ja) | Ｃ型肝炎ウイルスに特異的な細胞障害性ｔ細胞を刺激するためのペプチド | |
| KR20010053042A (ko) | 구제역에 대한 합성 펩티드 백신 | |
| JP3694299B2 (ja) | Ｂ型肝炎ウイルスに対する細胞障害性ｔリンパ球の応答を誘発するペプチド | |
| Sakamoto et al. | Studies on the structures and antigenic properties of rabies virus glycoprotein analogues produced in yeast cells | |
| JP5290576B2 (ja) | 修飾されたｈｉｖ−１エンベロープタンパク質 | |
| US5840303A (en) | Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus | |
| WO1998028004A1 (en) | Hepatitis delta particle containing a fusion protein immunogen | |
| PT671947E (pt) | Composicoes para produzir respostas de linfocitos t citotoxicas contra virus | |
| US20020086403A1 (en) | Pro-apoptotic fragments of the dengue virus envelope glycoproteins | |
| EP1324770A2 (en) | Non-replicative particulate vaccine delivery system and methods of making and using same | |
| KR960015513B1 (ko) | 한국형 c형 간염 진단시약 및 백신 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Ref document number: 117974 Country of ref document: FI |
|
| MM | Patent lapsed |